Day: March 7, 2022

SYDNEY, Australia, March 07, 2022 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (“Iris Energy” or “the Company”), a leading sustainable Bitcoin miner which is building an institutional grade infrastructure platform with 15 EH/s of secured miners (10 EH/s expected to be operational by early 2023), announced today that its management team is scheduled to attend the following investor conferences. Attendance at these conferences is by invitation only for clients of each respective firm. Interested investors should contact their respective sales representative to register and to secure a time for one-on-one meetings.Thursday, March 17: Canaccord Genuity Blockchain Infrastructure & Mining Summit Thursday, March 24: Ladenburg Thalmann Special Crypto Expo Monday, March 28: Bank of America Crypto Mining DayAbout Iris Energy Iris...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) — (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) (LSE/STO/Nasdaq:​AZN). This milestone has been triggered by the initiation of start-up activities for SAFFRON, the first global Phase III study for ORPATHYS® in combination with TAGRISSO® in epidermal growth factor receptor (“EGFR”)-mutated non-small cell lung cancer (“NSCLC”) patients with mesenchymal epithelial transition receptor (“MET”) driven tumors following progression after TAGRISSO®. SAFFRON, which is expected to commence enrolling patients in mid-2022, follows important lessons learned from the SAVANNAH study, which is targeted to be presented at an upcoming scientific conference in the second...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 4, 2022 to its short form base shelf prospectus dated February 23, 2022. TORONTO, March 06, 2022 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; Nasdaq: DGHI) is pleased to announce that the Company has entered into a subscription agreement with a single institutional investor, for gross proceeds of approximately CAD$13.3 million in a private placement of its equity securities, comprised of 3,029,748 common shares of the Company (“Shares”) (or common share equivalents) and warrants to purchase up to 3,029,748 common shares (“Warrants”), at a purchase price of CAD$4.40 per Share and associated Warrant, representing a premium of more than 10% over the previous closing...

EMERYVILLE, Calif., March 06, 2022 (GLOBE NEWSWIRE) — Biotechnology company Zymergen (ZY) is pleased to announce early results from its work on infectious disease, discovering hundreds of potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow. This ambitious multi-target infectious disease program is supported through a grant from the Bill & Melinda Gates Foundation, enabling Zymergen to identify novel hits for all three target pathogens. The early progress has been enabled by Zymergen’s differentiated cheminformatics capabilities and ability to search their proprietary virtual compound database of Natural Products. “Virtual screening has...